Clinically	clinically	O	O	O	O
significant	significant	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
following	following	O	O	O	O
the	the	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
to	to	O	O	O	O
renal	renal	O	O	O	O
transplant	transplant	O	O	O	O
recipients	recipients	O	O	O	O
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
Sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
the	the	O	O	O	O
latest	latest	O	O	O	O
immunosuppressive	immunosuppressive	O	O	O	O
agent	agent	O	O	O	O
used	used	O	O	O	O
to	to	O	O	O	O
prevent	prevent	O	O	O	O
rejection	rejection	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
may	may	O	O	O	O
have	have	O	O	O	O
less	less	O	O	O	O
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
than	than	O	O	O	O
calcineurin	calcineurin	O	O	O	O
inhibitor	inhibitor	O	O	O	O
(CNI)-based	(cni)-based	O	O	O	O
regimens	regimens	O	O	O	O
.	.	O	O	O	O

To	to	O	O	O	O
date	date	O	O	O	O
there	there	O	O	O	O
has	has	O	O	O	O
been	been	O	O	O	O
little	little	O	O	O	O
documentation	documentation	O	O	O	O
of	of	O	O	O	O
clinically	clinically	O	O	O	O
significant	significant	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
linked	linked	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
have	have	O	O	O	O
encountered	encountered	O	O	O	O
several	several	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
developed	developed	O	O	O	O
substantial	substantial	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
associated	associated	O	O	O	O
with	with	O	O	O	O
sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
use	use	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
each	each	O	O	O	O
patient	patient	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
close	close	O	O	O	O
temporal	temporal	O	O	O	O
association	association	O	O	O	O
between	between	O	O	O	O
the	the	O	O	O	O
commencement	commencement	O	O	O	O
of	of	O	O	O	O
sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
and	and	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
implicated	implicated	O	O	O	O
sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
as	as	O	O	O	O
the	the	O	O	O	O
most	most	O	O	O	O
likely	likely	O	O	O	O
etiology	etiology	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
We	we	O	O	O	O
analyzed	analyzed	O	O	O	O
the	the	O	O	O	O
clinical	clinical	O	O	O	O
and	and	O	O	O	O
laboratory	laboratory	O	O	O	O
information	information	O	O	O	O
available	available	O	O	O	O
for	for	O	O	O	O
all	all	O	O	O	O
119	119	O	O	O	O
patients	patients	O	O	O	O
transplanted	transplanted	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
Washington	washington	O	O	O	O
Hospital	hospital	O	O	O	O
Center	center	O	O	O	O
between	between	O	O	O	O
1999	1999	O	O	O	O
-	-	O	O	O	O
2003	2003	O	O	O	O
for	for	O	O	O	O
whom	whom	O	O	O	O
sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
a	a	O	O	O	O
component	component	O	O	O	O
of	of	O	O	O	O
their	their	O	O	O	O
immunosuppressant	immunosuppressant	O	O	O	O
regimen	regimen	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
these	these	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
magnitude	magnitude	O	O	O	O
of	of	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
was	was	O	O	O	O
assessed	assessed	O	O	O	O
on	on	O	O	O	O
morning	morning	O	O	O	O
urine	urine	O	O	O	O
samples	samples	O	O	O	O
by	by	O	O	O	O
turbidometric	turbidometric	O	O	O	O
measurement	measurement	O	O	O	O
or	or	O	O	O	O
random	random	O	O	O	O
urine	urine	O	O	O	O
protein	protein	O	O	O	O
:	:	O	O	O	O
creatinine	creatinine	CHEMICALS	O	OTHERS	I
ratios	ratios	O	O	O	O
,	,	O	O	O	O
an	an	O	O	O	O
estimate	estimate	O	O	O	O
of	of	O	O	O	O
grams	grams	O	O	O	O
of	of	O	O	O	O
proteinuria/day	proteinuria/day	O	O	O	O
.	.	O	O	O	O

Laboratory	laboratory	O	O	O	O
results	results	O	O	O	O
were	were	O	O	O	O
compared	compared	O	O	O	O
between	between	O	O	O	O
prior	prior	O	O	O	O
,	,	O	O	O	O
during	during	O	O	O	O
and	and	O	O	O	O
following	following	O	O	O	O
sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
use	use	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Twenty-eight	twenty-eight	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
24	24	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
developed	developed	O	O	O	O
increased	increased	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
from	from	O	O	O	O
baseline	baseline	O	O	O	O
during	during	O	O	O	O
their	their	O	O	O	O
post-transplantation	post-transplantation	O	O	O	O
course	course	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
21	21	O	O	O	O
patients	patients	O	O	O	O
an	an	O	O	O	O
alternative	alternative	O	O	O	O
cause	cause	O	O	O	O
of	of	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
was	was	O	O	O	O
either	either	O	O	O	O
obvious	obvious	O	O	O	O
or	or	O	O	O	O
insufficient	insufficient	O	O	O	O
data	data	O	O	O	O
was	was	O	O	O	O
available	available	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
conclusive	conclusive	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
7	7	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
28	28	O	O	O	O
patients	patients	O	O	O	O
there	there	O	O	O	O
was	was	O	O	O	O
a	a	O	O	O	O
striking	striking	O	O	O	O
temporal	temporal	O	O	O	O
association	association	O	O	O	O
between	between	O	O	O	O
the	the	O	O	O	O
initiation	initiation	O	O	O	O
of	of	O	O	O	O
sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
nephrotic-range	nephrotic-range	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Proteinuria	proteinuria	O	DISEASE	OTHERS	I
correlated	correlated	O	O	O	O
most	most	O	O	O	O
strongly	strongly	O	O	O	O
with	with	O	O	O	O
sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
when	when	O	O	O	O
compared	compared	O	O	O	O
to	to	O	O	O	O
other	other	O	O	O	O
demographic	demographic	O	O	O	O
and	and	O	O	O	O
clinical	clinical	O	O	O	O
variables	variables	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
most	most	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
discontinuation	discontinuation	O	O	O	O
of	of	O	O	O	O
sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
resulted	resulted	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
decrease	decrease	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
not	not	O	O	O	O
resolution	resolution	O	O	O	O
,	,	O	O	O	O
of	of	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
Sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
induces	induces	O	O	O	O
or	or	O	O	O	O
aggravates	aggravates	O	O	O	O
pre-existing	pre-existing	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
in	in	O	O	O	O
an	an	O	O	O	O
unpredictable	unpredictable	O	O	O	O
subset	subset	O	O	O	O
of	of	O	O	O	O
renal	renal	O	O	O	O
allograft	allograft	O	O	O	O
recipients	recipients	O	O	O	O
.	.	O	O	O	O

Proteinuria	proteinuria	O	DISEASE	OTHERS	I
may	may	O	O	O	O
improve	improve	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
does	does	O	O	O	O
not	not	O	O	O	O
resolve	resolve	O	O	O	O
,	,	O	O	O	O
when	when	O	O	O	O
sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
withdrawn	withdrawn	O	O	O	O
.	.	O	O	O	O

